Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.

J Oncol Pharm Pract · 2018 · PMC6094503 · PMID 28614980

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the pooled comparison, the risk of FN was lower with LIP than PEG, but did not reach statistical significance (risk ratio (RR) = 0.34, 95% CI: 0.05, 2.14).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.